Idorsia Ltd

SWX:IDIA Aktierapport

Börsvärde: CHF 1.6b

Idorsia Framtida tillväxt

Future kriterier kontrolleras 4/6

Idorsia förväntas öka vinsten och intäkterna med 80.2% och 18.5% per år respektive medan EPS förväntas växa med 80.4% per år.

Viktig information

80.2%

Tillväxttakt i vinsten

80.42%

Tillväxttakt för EPS

Biotechs vinsttillväxt23.9%
Intäkternas tillväxttakt18.5%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Low

Senast uppdaterad31 Jul 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • Jul 31

IDIA: Future Pediatric Sleep And Vaccine Pipeline May Not Justify Current Optimism

Analysts have raised their price target on Idorsia by CHF 0.50 to CHF 4.50, citing updated assumptions on fair value, revenue growth, profit margin and future P/E expectations. What’s in the News for Idorsia Idorsia reported QUVIVIQ sales of CHF 91 million for the first half of 2026, with the company reaffirming its full year 2026 guidance and highlighting four key drivers of future growth, including QUVIVIQ market expansion and TRYVIO/JERAYGO commercialization.
Uppdatering av berättelse • Jul 10

IDIA: Future CEO Transition And Debt Refinancing Will Test Equity Downside

Analysts recently lifted their price target on Idorsia to CHF 4.50 from CHF 4.00, citing updated assumptions for revenue growth, profit margins, discount rates and future P/E levels in their valuation work. What’s in the News for Idorsia Idorsia appointed Roland Wandeler, PhD, as Chief Executive Officer effective October 1, 2026.
Uppdatering av berättelse • Jun 26

IDIA: Pharmakon Debt Will Likely Constrain Long-Term Upside Potential

Analysts recently lifted their price target on Idorsia stock from CHF 4.00 to CHF 4.50, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What’s in the News for Idorsia Idorsia confirmed the closing of a senior secured term loan of up to CHF 250 million with funds managed by Pharmakon Advisors.
Uppdatering av berättelse • Jun 05

IDIA: Pediatric Sleep And Vaccine Pipeline Will Support Future Upside Despite Higher Costs

Analysts have lowered their price target on Idorsia to CHF 5, down from CHF 6. They cite reduced forward visibility and higher operating expenses as the main reasons for this adjustment.
Uppdatering av berättelse • May 04

IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs

Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.
Uppdatering av berättelse • Apr 18

IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs

Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.
Uppdatering av berättelse • Apr 04

IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside

Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.
Uppdatering av berättelse • Mar 20

IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside

Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.
Uppdatering av berättelse • Mar 05

IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside

Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.
Uppdatering av berättelse • Feb 19

IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside

Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).
Uppdatering av berättelse • Feb 04

IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside

Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.
Uppdatering av berättelse • Jan 21

IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside

Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.
Uppdatering av berättelse • Jan 07

IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside

Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.
Analysartikel • Dec 22

Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...
Uppdatering av berättelse • Dec 17

IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels

Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).
Uppdatering av berättelse • Dec 03

IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price

Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).
Uppdatering av berättelse • Nov 19

IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment

Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.
Analysartikel • Nov 07

Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding

The Idorsia Ltd ( VTX:IDIA ) share price has softened a substantial 29% over the previous 30 days, handing back much of...
Uppdatering av berättelse • Nov 03

IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift

Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.
Uppdatering av berättelse • Sep 23

Global Expansion And FDA Review Will Moderate Overvaluation

Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.
Analysartikel • Sep 14

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Idorsia Ltd ( VTX:IDIA ) shares have continued their recent momentum with a 38% gain in the last month alone. The...
Ny berättelse • Sep 08

Global Expansion And FDA Review Will Moderate Overvaluation

Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.
Analysartikel • Aug 24

New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)

Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the covering analyst has just delivered a major...
Analysartikel • Jul 19

There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump

Despite an already strong run, Idorsia Ltd ( VTX:IDIA ) shares have been powering on, with a gain of 46% in the last...
Analysartikel • Dec 19

Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified

Idorsia Ltd ( VTX:IDIA ) shareholders are no doubt pleased to see that the share price has bounced 71% in the last...
Analysartikel • Nov 06

One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts

The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the covering analyst making...
Analysartikel • Nov 04

Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower

To the annoyance of some shareholders, Idorsia Ltd ( VTX:IDIA ) shares are down a considerable 33% in the last month...
Analysartikel • Sep 18

Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper

The Idorsia Ltd ( VTX:IDIA ) share price has fared very poorly over the last month, falling by a substantial 25%. For...

Prognoser för vinst- och omsättningstillväxt

SWX:IDIA - Analytikernas framtida uppskattningar och tidigare finansiella data (CHF Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202834741N/AN/A2
12/31/2027265-66N/AN/A3
12/31/2026239-121N/AN/A1
6/30/2026200-316-126-118N/A
3/31/2026219-221-134-119N/A
12/31/2025221-112-167-153N/A
9/30/2025233-118-133-121N/A
6/30/2025217-133-263-251N/A
3/31/2025161-230-330-313N/A
12/31/2024113-264-388-370N/A
9/30/202474-296-488-470N/A
6/30/202412829-422-403N/A
3/31/2024141-56-504-498N/A
12/31/2023152-298-639-629N/A
9/30/2023185-374-751-739N/A
6/30/2023126-814-874-859N/A
3/31/2023113-843-889-871N/A
12/31/202297-828-886-859N/A
9/30/202248-887-868-836N/A
6/30/202244-810-788-756N/A
3/31/202234-728-719-678N/A
12/31/202135-635-621-590N/A
9/30/202136-520-542-515N/A
6/30/202127-499-513-491N/A
3/31/202174-429-419-409N/A
12/31/202072-445-374-365N/A
9/30/202070-450-379-367N/A
6/30/202069-451-417-400N/A
3/31/202022-507N/A-459N/A
12/31/201924-494N/A-462N/A
9/30/201961-460N/A-461N/A
6/30/201961-459N/A-430N/A
3/31/201961-414N/A-391N/A
12/31/201861-386N/A-353N/A
9/30/2018209-213N/A-63N/A
6/30/2018203-165N/A-25N/A
12/31/2017190-17N/A115N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: IDIA förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 0.6% ).

Resultat vs marknad: IDIA förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: IDIA förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: IDIA s intäkter ( 18.5% per år) förväntas växa snabbare än Swiss marknaden ( 5.3% per år).

Hög tillväxtintäkter: IDIA s intäkter ( 18.5% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om IDIA s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/08/09 16:31
Aktiekurs vid dagens slut2026/08/07 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Idorsia Ltd bevakas av 10 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Rosie TurnerBarclays
Alistair CampbellBerenberg
Sachin JainBofA Global Research